134 related articles for article (PubMed ID: 38241910)
1. Plasma metabolites analysis of patients with papillary thyroid cancer: A preliminary untargeted
Razavi SA; Mahmanzar M; Nobakht M Gh BF; Zamani Z; Nasiri S; Hedayati M
J Pharm Biomed Anal; 2024 Apr; 241():115946. PubMed ID: 38241910
[TBL] [Abstract][Full Text] [Related]
2. Non-invasive diagnosis of papillary thyroid microcarcinoma: a NMR-based metabolomics approach.
Lu J; Hu S; Miccoli P; Zeng Q; Liu S; Ran L; Hu C
Oncotarget; 2016 Dec; 7(49):81768-81777. PubMed ID: 27835583
[TBL] [Abstract][Full Text] [Related]
3. Serum-plasma matched metabolomics for comprehensive characterization of benign thyroid nodule and papillary thyroid carcinoma.
Huang FQ; Li J; Jiang L; Wang FX; Alolga RN; Wang MJ; Min WJ; Ma G; Zhao YJ; Wang SL; Yu Y; Chen X; Zhu D; Zhu J; Wang G; Xia T; Sang JF; Lai MD; Li P; Zhu W; Qi LW
Int J Cancer; 2019 Feb; 144(4):868-876. PubMed ID: 30318614
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of papillary thyroid carcinoma by
Wang T; Sun Z; Wang Y; Li F; Zhou X; Tian X; Wang S
Drug Discov Ther; 2020 Sep; 14(4):187-196. PubMed ID: 32848112
[TBL] [Abstract][Full Text] [Related]
5. Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy.
Shang X; Zhong X; Tian X
Tumour Biol; 2016 Aug; 37(8):11163-75. PubMed ID: 26935059
[TBL] [Abstract][Full Text] [Related]
6. Combined metabolomic and lipidomic analysis uncovers metabolic profile and biomarkers for papillary thyroid carcinoma.
Wang Z; Yang Y; Xing Y; Si D; Wang S; Lin J; Li C; Zhang J; Yin D
Sci Rep; 2023 Oct; 13(1):17666. PubMed ID: 37848492
[TBL] [Abstract][Full Text] [Related]
7. Plasma Metabolic Profiling of Human Thyroid Nodules by Gas Chromatography-Mass Spectrometry (GC-MS)-Based Untargeted Metabolomics.
Abooshahab R; Hooshmand K; Razavi SA; Gholami M; Sanoie M; Hedayati M
Front Cell Dev Biol; 2020; 8():385. PubMed ID: 32612989
[TBL] [Abstract][Full Text] [Related]
8. Metabolic changes associated with papillary thyroid carcinoma: A nuclear magnetic resonance-based metabolomics study.
Li Y; Chen M; Liu C; Xia Y; Xu B; Hu Y; Chen T; Shen M; Tang W
Int J Mol Med; 2018 May; 41(5):3006-3014. PubMed ID: 29484373
[TBL] [Abstract][Full Text] [Related]
9. The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer.
Zarkesh M; Zadeh-Vakili A; Akbarzadeh M; Fanaei SA; Hedayati M; Azizi F
BMC Cancer; 2018 Dec; 18(1):1199. PubMed ID: 30509240
[TBL] [Abstract][Full Text] [Related]
10. Incidentally Discovered Papillary Thyroid Microcarcinomas Are More Frequently Found in Patients with Chronic Lymphocytic Thyroiditis Than with Multinodular Goiter or Graves' Disease.
Paparodis RD; Karvounis E; Bantouna D; Chourpiliadis C; Chourpiliadi H; Livadas S; Imam S; Jaume JC
Thyroid; 2020 Apr; 30(4):531-535. PubMed ID: 31950881
[No Abstract] [Full Text] [Related]
11. Metabolite analysis-aided diagnosis of papillary thyroid cancer.
Chen J; Hu Q; Hou H; Wang S; Zhang Y; Luo Y; Chen H; Deng H; Zhu H; Zhang L; Liu H; Wang A; Liu Y
Endocr Relat Cancer; 2019 Dec; 26(12):829-841. PubMed ID: 31671400
[TBL] [Abstract][Full Text] [Related]
12. Integrative metabolomic characterization identifies plasma metabolomic signature in the diagnosis of papillary thyroid cancer.
Yu S; Liu C; Hou Y; Li J; Guo Z; Chen X; Zhang L; Peng S; Hong S; Xu L; Li X; Liu R; Chen S; Li B; Weng Z; Li Y; Lv W; Yu J; Xiao H
Oncogene; 2022 Apr; 41(17):2422-2430. PubMed ID: 35279704
[TBL] [Abstract][Full Text] [Related]
13. Circulating levels of PTEN and KLLN in papillary thyroid carcinoma: can they be considered as novel diagnostic biomarkers?
Razavi SA; Modarressi MH; Yaghmaei P; Tavangar SM; Hedayati M
Endocrine; 2017 Sep; 57(3):428-435. PubMed ID: 28755140
[TBL] [Abstract][Full Text] [Related]
14. Serum-based metabolic alterations in patients with papillary thyroid carcinoma unveiled by non-targeted 1H-NMR metabolomics approach.
Farrokhi Yekta R; Rezaei Tavirani M; Arefi Oskouie A; Mohajeri-Tehrani MR; Soroush AR; Akbarzadeh Baghban A
Iran J Basic Med Sci; 2018 Nov; 21(11):1140-1147. PubMed ID: 30483387
[TBL] [Abstract][Full Text] [Related]
15. Low level of plasma fibulin-1 in patients with thyroid lesions: a case-control study and literature review.
Hedayati M; Abooshahab R; Razavi SA; Salehipour P; Ahmadikia K; Boroomand S
Mol Biol Rep; 2020 Nov; 47(11):8859-8866. PubMed ID: 33106982
[TBL] [Abstract][Full Text] [Related]
16. Metabolomics as a potential method for predicting thyroid malignancy in children and adolescents.
Zhou Q; Zhang LY; Xie C; Zhang ML; Wang YJ; Liu GH
Pediatr Surg Int; 2020 Feb; 36(2):145-153. PubMed ID: 31576470
[TBL] [Abstract][Full Text] [Related]
17. Metabolite signature of human malignant thyroid tissue: A systematic review and meta-analysis.
Razavi SA; Khorsand B; Salehipour P; Hedayati M
Cancer Med; 2024 Apr; 13(8):e7184. PubMed ID: 38646957
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Profiles and Blood Biomarkers to Discriminate between Benign Thyroid Nodules and Papillary Carcinoma, Based on UHPLC-QTOF-ESI
Berinde GM; Socaciu AI; Socaciu MA; Petre GE; Socaciu C; Piciu D
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542465
[TBL] [Abstract][Full Text] [Related]
19. Study on plasmatic metabolomics of Uygur patients with essential hypertension based on nuclear magnetic resonance technique.
Zhong L; Zhang JP; Nuermaimaiti AG; Yunusi KX
Eur Rev Med Pharmacol Sci; 2014; 18(23):3673-80. PubMed ID: 25535139
[TBL] [Abstract][Full Text] [Related]
20. Complement C4-A and Plasminogen as Potential Biomarkers for Prediction of Papillary Thyroid Carcinoma.
Wang Y; Zhou S; Wang D; Wei T; Zhu J; Li Z
Front Endocrinol (Lausanne); 2021; 12():737638. PubMed ID: 34803909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
